T A B L E O F C O N T E N

Main results
We included two randomized clinical trials involving 69 participants. Both trials compared carvedilol against placebo, and had a high risk of bias. Carvedilol compared with placebo did not significantly affect all-cause mortality (2/34 (5.88%) versus 3/35 (5.87%); pooled RR 0.69, 95% CI 0.12 to 3.88, I 2 = 0%). None of the trials reported on cardiovascular mortality, time to heart decompensation or disease-free period. Evidence on the adverse effects of carvedilol is inconclusive.
Authors' conclusions
This Cochrane review has found a lack of evidence on the effects of carvedilol for treating heart failure in patients with Chagas disease. The two included trials were underpowered and had a high risk of bias. There are no conclusive data to support the use of carvedilol for treating Chagas cardiomyopathy. Unless randomized clinical trials provide evidence of a treatment effect, and the trade off between potential benefits and harms is established, policy-makers, clinicians, and academics should be cautious when recommending and administering carvedilol for treating heart failure in patients with Chagas disease. The efficacy and safety of other pharmacological interventions for treating heart failure in patients with Chagas disease is unknown.
P L A I N L A N G U A G E S U M M A R Y
Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy
Named in honor of the Brazilian physician Carlos Chagas, Chagas disease is caused by the Trypanosoma cruzi parasite which needs humans for the start of its life cycle. It is common in Latin and Central America and leads to Chagas cardiomyopathy (heart muscle disease), and is an important cause of heart failure. The number of people infected with Chagas disease has been estimated to be about 10 to 12 million worldwide, and around 20% to 30% of individuals infected with Trypanosoma cruzi will develop symptomatic heart disease at some point during their lives.
In the Americas in 2005 there were estimated to be 7,694,500 people infected by Trypanosoma cruzi and 1,772,365 suffering from Chagasic cardiopathy. Furthermore, infected people from endemic countries in Latin America are migrating throughout the world. As a result, what was thought to be an American health problem is rapidly becoming a world health problem. It has been estimated that 300,167 individuals with Trypanosoma cruzi infection live in the United States, with 30,000 to 45,000 cardiomyopathy cases and 63 to 315 congenital infections annually.
Standard treatment options for non-Chagas disease heart failure are used for treating Chagas disease-related heart failure. There is a need to assess the benefits and harms of pharmacological interventions for Chagas disease-related heart failure, due to fundamental differences in the affected populations. This Cochrane review identified two randomized clinical trials of these interventions, involving 69 participants. These trials evaluated the use of carvedilol against placebo in the treatment of heart failure in people with Chagas cardiomyopathy. We found no significant difference between carvedilol and placebo in reducing all-cause mortality. The safety profile of carvedilol for Chagas cardiomyopathy remains unclear. These results are based on trials at high risk of bias. The existing evidence from available clinical trials does not support the use of carvedilol in treating heart failure in patients with Chagas cardiomyopathy. Further investigation is warranted to investigate the exact applicability of conventional heart failure treatment agents in Chagas cardiomyopathy. Preventive approaches such as control of the Triatomine bug and ecological niche studies are key to reducing the incidence of Chagas disease.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Patient or population: chronic heart failure in Chagas cardiomyopathy patients
Settings:
outpatients Intervention: 
CI: Confidence interval; RR:
Risk ratio;
GRADE Working Group grades of evidence High quality:
Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality:
Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality:
Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality:
We are very uncertain about the estimate.
1
Two Brazilian randomized clinical trials.
2
Random sequence generation, allocation concealment and blinding at any level: unclear risk of bias. One of the clinical forms of Chagas disease is "Chagas disease (chronic) with heart involvement" (Labarthe 1998). Chagas disease is still a major cause of heart failure in South America (Mendez The risk of mortality in patients affected by Chagas disease includes three stages: low (total mortality 2% and 10% at five years and 10 years respectively), intermediate (total mortality 18% and 44% at five years and 10 years respectively) and high (total mortality 63% and 84% at five years and 10 years respectively) (Rassi Jr 2010). This stratification of risk death has led to the following recommended approaches (Rassi Jr 2010): 1. Possibly antiparasitic drug for low stage without New York Heart Association (NYHA) class III or IV, left ventricular systolic dysfunction (echocardiography) or cardiomegaly (chest radiography), or both, and non-sustained ventricular tachycardia (24-h Holter monitoring).
2. Possibly treat with amiodarone and an antiparasitic drug for intermediate stage without NYHA class III or IV, left ventricular systolic dysfunction (echocardiography) or cardiomegaly (chest radiography), or both; but, with non-sustained ventricular tachycardia (24-h Holter monitoring).
3. Angiotensin-converting enzyme inhibitors, beta-blockers, diuretics (for selected patients), possibly treat with an antiparasitic drug for intermediate stage without NYHA class III or IV, with left ventricular systolic dysfunction (echocardiography) or cardiomegaly (chest radiography), or both; and absent non-sustained ventricular tachycardia (24-h Holter monitoring).
4. Angiotensin-converting enzyme inhibitors, amiodarone, diuretics (for selected patients), beta-blockers (if clinically tolerated), possibly treat with an implantable cardioverter defibrillator for high stage without NYHA class III or IV, with left ventricular systolic dysfunction (echocardiography) or cardiomegaly (chest radiography), or both; and with nonsustained ventricular tachycardia (24-h Holter monitoring).
5. Angiotensin-converting enzyme inhibitors, spironolactone, amiodarone, diuretics, digitalis, beta-blockers (if clinically tolerated), heart transplantation (if clinically tolerated), possibly treat with an implantable cardioverter defibrillator for high stage with NYHA class III or IV, with left ventricular systolic dysfunction (echocardiography) or cardiomegaly (chest radiography), or both; and with non-sustained ventricular tachycardia (24-h Holter monitoring). All of the above pharmacological approaches are based on expert opinion rather than evidence of benefit.
Description of the intervention
In Chagas disease, the haemodynamic and neurohormonal responses are similar to those in other cardiomyopathies. This common pathophysiology suggests that therapies effective in usual heart failure cases should also be beneficial in Chagas disease (Botoni 2007). Pharmacological agents such as angiotensin-converting enzyme inhibitors and beta-blockers are likely to be important in Chagas disease as in other heart failure syndromes (Biolo 2010). Serious adverse events have been observed with these medications in chronic heart failure. See Appendix 1 for adverse events from pharmacological therapy to treat heart failure. Pharmacological interventions for treating heart failure include many different families of drugs ( 
How the intervention might work
The above-mentioned pharmacological interventions work through many different mechanisms (Hamad 2007).
1. Angiotensin-converting enzyme inhibitors reduce angiotensin II production by blocking the plasma and pulmonary endothelial angiotensin-converting enzyme. Angiotensin II produces deleterious cardiovascular effects including direct vasoconstriction, increased sympathetic discharge, release of catecholamines, increased sodium reabsorption in the proximal tubule, and the release of aldosterone.
2. Angiotensin II receptor antagonists block the effects of the angiotensin II which generates activation of two types of receptors on the cell surface: angiotensin II type 1 and angiotensin II type 2. Angiotensin II receptor antagonists type1 mediates vasoconstriction and stimulates aldosterone and vasopressin secretion which causes sodium and water retention.
3. Aldosterone receptor antagonists reduce the action of aldosterone, a hormone produced by the adrenal glands. Aldosterone causes vasoconstriction, increases salt and water retention, and stimulates the growth of fibroblasts and the synthesis of collagen.
4. Inotropes causes increased inotropic effects and vasodilation independent of the stimulation of beta-receptors (milrinone) or through the stimulation of the of beta-receptors of the heart. 5. Digitalis leads to increased myocardial contractility through the increase of intracellular calcium.
6. Diuretics increase the excretion of the sodium and water, which reduces fluid retention.
7. Vasodilators reduce afterload and preload by dilating both arterial and venous blood vessels.
8. Beta-adrenoceptor antagonists reduce the sympathetic nervous system and renin-angiotensin system. 9. Calcium sensitizers increase myocardial contractility.
Why it is important to do this review
A review of the evidence for treating heart failure associated with Chagas disease is required for the following reasons: 1. Chagas disease is a major cause of morbidity and mortality in Latin America (Rassi 2000; Schmunis 2010).
2. Although there are published systematic reviews of the effect of trypanocidal drugs for the different stages of Chagas disease (Reyes 2005; Villar 2002), no systematic review of the pharmacological interventions commonly used in chronic heart failure has been conducted for Chagas disease.
3. The management of Chagas disease may be even more difficult than that of other dilated cardiomyopathies (Dobarro 2008) . This worse prognosis may be due to a greater degree of cardiac impairment (lower ejection fraction) and haemodynamic instability (lower systolic blood pressure and heart rate), increased activation of the renin-angiotensin system, and increased cytokine levels (Silva 2008). Therefore, there are uncertainties in using pharmacological interventions and the rates of their adverse effects. Drugs for treating heart failure are associated with severe adverse events which, in patients with Chagas disease, could be life-threatening.
4. The increasing number of people affected by Chagas disease emigrating from the Americas to developed countries may cause a radical increase in the incidence of this disease over the coming years; however, European cardiologists are unfamiliar with this Table 2 ).
5. A review is needed to improve patient care through the therapeutic decision making based on the best evidence-based treatment. This Cochrane review updates current knowledge and resolve any uncertainties. Our research question was: "What is the benefit and harm of pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy?" Appendix 2 provides a medical glossary.
O B J E C T I V E S
To assess the benefits and harms of current pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy disease, mainly on the clinical end points such as: all-cause mortality, overall survival, quality of life, adverse events.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized clinical trials irrespective of publication status (trials may be unpublished or published as an article, an abstract, or a letter). No language, country and sample size limitations were applied. We included trials conducted in either a hospital or community setting, or both. No limits were applied with respect to period of follow-up.
Types of participants
Adults (≥18 years) with symptomatic heart failure (New York Heart Association class II to IV) (Table 3) irrespective of the left ventricular ejection fraction stage, reduced or preserved, in patients with Chagas cardiomyopathy. We considered trials evaluating pharmacotherapies in a general heart failure population including participants affected by Chagas cardiomyopathy. 
Types of interventions
Searching other resources
We searched the Clinical Trials Search Portal of the World Health Organization (http://apps.who.int/trialsearch/) for ongoing and unpublished trials (Appendix 8). We also searched Clinicaltrials.gov for ongoing and other relevant trials (Appendix 9). We also checked the reference lists of all the trials identified by the above methods.
Data collection and analysis
Selection of studies
Two authors (SD, DS) independently assessed each reference to see whether it met the inclusion criteria. Any disagreements were resolved through discussion with other co-authors (RH, AM-C).
Data extraction and management
Two authors (SN,DS) independently extracted data from the selected trials using a standardized data extraction form. Any disagreements were resolved through discussion with the other authors (RH, AM-C). We also contacted Dr Viana Zuza Diniz who sent us the full text of her PhD thesis (Diniz 2004).
Assessment of risk of bias in included studies
Three authors (RH, AM-C, and DS) independently assessed the risk of bias of each trial using a simple form following the domainbased evaluation as described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). This section was checked by Joey Kwong. We assessed the following domains:
1. Generation of the allocation sequence. • Low risk, if the allocation sequence was generated by a computer or random number table. Drawing of lots, tossing of a coin, shuffling of cards, or throwing dice was considered as adequate if a person who was not otherwise involved in the recruitment of participants performed the procedure.
• Unclear risk, if the trial was described as randomized, but the method used for the allocation sequence generation was not described.
• High risk, if a system involving dates, names, or admittance numbers was used for the allocation of patients.
Allocation concealment
• Low risk, if the allocation of patients involved a central independent unit, on-site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes.
• Unclear risk, if the trial was described as randomized, but the method used to conceal the allocation was not described.
• High risk, if the allocation sequence was known to the investigators who assigned participants or if the study was quasirandomized.
Blinding (or masking)
We assessed each trial (as Low, Unclear, or High risk) with regard to the following types of blinding:
• blinding of clinician (person delivering treatment) to treatment allocation;
• blinding of participant to treatment allocation;
• blinding of outcome assessor to treatment allocation.
Incomplete outcome data
• Low risk, the numbers and reasons for dropouts and withdrawals in all intervention groups were described or if it was specified that there were no dropouts or withdrawals.
• Unclear risk, the report gave the impression that there had been no dropouts or withdrawals, but this was not specifically stated.
• High risk, the number or reasons for dropouts and withdrawals were not described.
We further examined the percentages of dropouts overall in each trial and per randomization arm and we evaluated whether intention-to-treat analysis was performed or could be performed from the published information.
Selective outcome reporting
• Low risk, if pre-defined or clinically relevant and reasonably expected outcomes were reported on.
• Unclear risk, if not all pre-defined or clinically relevant and reasonably expected outcomes were reported on or were not reported on fully, or it was unclear whether data on these outcomes were recorded or not.
• High risk, if one or more clinically relevant and reasonably expected outcomes were not reported on; data on these outcomes were likely to have been recorded.
Other bias (Baseline imbalance, early stopping, drug company involvement):
• Low risk, the trial appears to be free of other components that could put it at risk of bias.
• Unclear risk, the trial may or may not be free of other components that could put it at risk of bias.
• High risk, there are other factors in the trial that could put it at risk of bias, e.g., early stopping, industry involvement, or an extreme baseline imbalance.
We considered low-risk of bias trials to be those that adequately generated their allocation sequence; had adequate allocation concealment, adequate blinding, adequate handling of incomplete outcome data; were free of selective outcome reporting; and were free of other bias. We considered trials in which we assessed at least one of the domains as having a high risk of bias or unclear risk of bias, to be trials with high risk of bias.
Measures of treatment effect
We calculated the relative risk with 95% confidence intervals for the following binary outcomes: all-cause mortality and safety.
Dealing with missing data
We assessed the percentages of dropouts overall for each included trial and per each randomization arm and we evaluated whether an intention to treat analysis had been performed or could be performed with the available published information. We contacted Dr Viana Zuza Diniz who sent us the full text of her PhD thesis (Diniz 2004). We conducted an intention-to-treat analysis.
Assessment of heterogeneity
We quantified statistical heterogeneity using the I 2 statistic, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (Higgins 2003). When heterogeneity was detected (I 2 > 50%) we attempted to identify the possible causes of heterogeneity (Higgins 2011).
Assessment of reporting biases
We did not assess publication bias by a funnel plot because we included only two trials. For future updates, we will attempt to assess whether the review is subject to publication bias by using a funnel plot if ≥10 trials are included.
Data synthesis
We pooled the results from the trials using Review Manager software (RevMan 2011). We summarized findings using a fixed-effect model according the Cochrane Handbook of Systematic Reviews for Interventions (Higgins 2011).
'Summary of findings'
We used the principles of the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system to assess the quality of the body of evidence associated with specific outcomes (all-cause mortality) in our review (Balshem 2011; Brozek 2011; Guyatt 2008; Guyatt 2011h). The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality of a body of evidence takes into consideration within study risk of bias (methodological quality), the directness of the evidence, heterogeneity of the data, precision of effect estimates and risk of publication bias (Guyatt 2011a; Guyatt 2011b; Guyatt 2011c; Guyatt 2011d; Guyatt 2011e; Guyatt 2011f; Guyatt 2011g). For future updates, we will also assess the quality of the body of evidence associated with specific outcomes (all-cause mortality, quality of life, overall survival, cardiac mortality at 30 days, time to heart decompensation, disease-free period (at 30 days, at 60 days and 90 days), hospital readmissions (heart failure-or adverse event -related), adherence grade, adverse events and digoxin toxicity).
Subgroup analysis and investigation of heterogeneity
In subsequent updates of this review, when sufficient data are available, we plan to carry out the following subgroup analyses:
1. By intervention. 2. New York Heart Association stage. 3. Conduction system disturbances. 4. Atrial and ventricular arrhythmias. 5. Chronic versus acute heart failure. 6. Heart failure with preserved ejection fraction: ≤ 40% versus > 40%. We will only perform subgroup analysis for primary outcomes. Sources of heterogeneity in the assessment of the primary outcome measure will be explored by subgroup analyses and meta-regression analyses. The meta-regression analyses will assess the effect of methodological quality (high versus low), route of administration (intramuscular versus intravenous), and patients' characteristics. We will only conduct meta-regression if ≥ 10 RCTs are included.
Sensitivity analysis
For future updates, we plan to conduct a sensitivity analysis comparing the results using all trials as follow:
1. Those trials with high methodological quality (studies classified as having a 'low risk of bias' versus those identified as having a 'high risk of bias') (Higgins 2011); 2. Those trials that performed intention-to treat versus perprotocol analyses. We will also evaluate the risk of attrition bias, as estimated by the percentage of participants lost. Trials with a total attrition of more than 30%, or where differences between the groups exceed 10%, or both, will be excluded from meta-analysis but will be included in the review.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of ongoing studies.
Results of the search
We identified 1125 references using our search strategies, and assessed 6 of these in full text. A seventh study is ongoing ( NCT00323973). We excluded four studies (see Excluded studies). 
Included studies
We provide a detailed description of the included trials in the Characteristics of included studies. Overall, the mean age of the participants was 48.3 years (standard deviation (SD) 0.42). The percentage of included male participants was 74.2% (SD 3.96). 
Excluded studies
We excluded four references. Two were case reports (Bestetti 2010; Dávila 2002a), one reference was an editorial (Dávila 2008), and one was a non-randomized controlled trial (Issa 2010). See the Characteristics of excluded studies table.
Ongoing studies
We identified one ongoing study (NCT00323973). See Characteristics of ongoing studies for details.
Risk of bias in included studies
Both trials were of low methodological quality overall. See Figure  3 and Figure 4 for risk of bias graph and summary. 
Effects of interventions
Primary outcomes
The two trials reported on only one of our outcomes of interest. No data were available on the other outcomes (30day cardiovascular mortality, time to heart decompensation, disease-free period at 30, 60 and 90 days).
All-cause mortality
Meta-analysis of two trials (69 participants, 5 events) showed carvedilol was associated with a non-statistically significant reduction in all-cause mortality compared with placebo (pooled RR 0.69, 95% CI 0.12 to 3.88, I 2 = 0%; P = 0.67) (Botoni 2007; Diniz 2004) (Analysis 1.1).
Secondary outcomes Overall survival
One trial found no significant difference between the carvedilol group and placebo group (P = 0.525) for overall survival (Diniz 2004).
Quality of life
Botoni 2007 found no significant change between the carvedilol group and the control group in quality of life as assessed by SF-36. Diniz 2004 used the Minnesota Living With Heart Failure Questionnaire and reported a statistically significant difference in the carvedilol group before and after treatment (55 ± 15.22 (pre-treatment) versus 23.54 ± 8.66 (post-treatment), P < 0.001), whereas the placebo group showed no significant benefit in improving quality of life (44.26 ± 15.22 (pre-treatment) versus 8.28 ± 17.78 (post-treatment), P < 0.001).
Adverse events
One trial found a significant reduction in systolic and diastolic blood pressure (Botoni 2007) . This trial reported changes in renal function and serum electrolytes in both groups (Botoni 2007). Botoni 2007 reported reductions in heart rate in the carvedilol and placebo groups, but there was no recorded episode of symptomatic bradycardia. Diniz 2004 found no significant differences in the adverse events assessed, namely NYHA functional class deterioration, abdominal pain, heart beats and dizziness.
D I S C U S S I O N
Summary of main results
This review of pharmacological interventions for treating heart failure in people with Chagas cardiomyopathy included two trials (69 participants) which assessed carvedilol (Botoni 2007; Diniz 2004 ). Their critical appraisal shows weak evidence for the use of carvedilol in treating heart failure in Chagas cardiomyopathy. We did not find significant differences for reducing all-cause mortality, overall survival, quality of life, and adverse events in patients with Chagas cardiomyopathy complicated by heart failure treated with carvedilol versus placebo. The studies did not evaluate main clinical outcomes such as cardiac mortality at 30 days, time to heart decompensation, disease-free period (at 30, 60 and 90 days), hospital readmissions (heart failure-or adverse event -related), adherence grade and digoxin toxicity (Botoni 2007; Diniz 2004). The benefits and harms of carvedilol versus placebo for treating heart failure in people with Chagas cardiomyopathy remain unclear. See the Summary of findings for the main comparison for details of all-cause mortality.
Overall completeness and applicability of evidence
Only two trials were found by this review and they failed to detect statistically significant differences between the groups. It has been pointed out that meta-analyses including a limited number of patients and events are prone to yield overestimated intervention effect estimates (Thorlund 2011).
When dealing with such neutral results, we need to keep in mind that 'absence of evidence' is not 'evidence of absence' (Altman 1995; Fermi Paradox). The fact that this review did not detect any differences between the two intervention groups does not imply that placebo and carvedilol have the same mortality risk. The first possible explanation is failure to determine an appropriate sample size (Schulz 1995; Green 2002). In a remarkable paper from 28 years ago, Freiman et al suggested that "many of the therapies labelled as 'no different from control' in trials using inadequate samples, have not received a fair test" and that "concern for the probability of missing an important therapeutic improvement because of small sample sizes deserves more attention in the planning of clinical trials" (Freiman 1978 ). In 1998, Moher et al emphasized that "most trials with negative results did not have large enough sample sizes to detect a 25% or a 50% relative difference" (Moher 1998). Moreover, it has been suggested that the most important therapies adopted in clinical practice have shown more modest benefits (Kirby 2002).
Quality of the evidence
The main source of bias in the included trials was the lack of detail in describing the generation of randomization sequences and the concealment of allocation (Botoni 2007; Diniz 2004) . Trials also lacked detail on their blinding processes. Our assessment of the risk of bias of the included studies has been described previously and a summary can be found in Figure 3 and Figure 4 . Included trials were generally considered to be at a high risk of bias. Uncertainty remains about possible harms from the interventions, due to a lack of detail in presenting safety data. See the Summary of findings for the main comparison shows details for all-cause mortality. 
Potential biases in the review process
In the process of performing a systematic review, there is a group of biases called significance-chasing biases (Ioannidis 2010). This group includes publication bias, selective outcome reporting bias, selective analysis reporting bias, and fabrication bias (Ioannidis 2010). Publication bias represents a major threat to the validity of systematic reviews, particularly in reviews that include small trials. This Cochrane review has a low risk of publication bias due to the thorough trial search process, through which we detected the primary source of Diniz 2004. Selective outcome reporting bias operates through suppression of information on specific outcomes and has similarities to study publication bias, in that 'negative' results remain unpublished (Ioannidis 2010 
A U T H O R S ' C O N C L U S I O N S Implications for practice
This Cochrane review provides evidence that carvedilol does not seem to reduce all-cause mortality in patients suffering from heart failure associated with Chagas cardiomyopathy. Furthermore, carvedilol does not seem to improve overall survival and quality of life, or to reduce adverse events. The results are based on two trials with high risk of bias involving 69 patients that assessed carvedilol compared with placebo. Therefore, prescription of this intervention for patients suffering from heart failure associated with Chagas cardiomyopathy can neither be supported nor rejected, unless new evidence from a large high-quality trial alters this conclusion. Consequently, policy-makers, clinicians, and academics should not yet recommend this drug for use in those patients. This Cochrane review does not provide evidence about other pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy.
Implications for research
This systematic review has highlighted a need for well-designed, high-quality randomized trial to assess the benefits and harms of pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy. The trial should include main clinical outcomes (patients-oriented outcomes) such as all-cause mortality, quality of life, overall survival, cardiac mortality at 30 days, time to heart decompensation, disease-free period (at 30 days, 60 days and 90 days), hospital readmissions (heart failure-or adverse event -related), adherence grade, adverse events and digoxin toxicity. 
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